Lv1
60 积分 2024-01-03 加入
Anti-PEG antibodies: Current situation and countermeasures
19小时前
已完结
Unleashing the potential of natural protein based nanoparticles for the delivery of therapeutic nucleic Acid: A comprehensive review
7天前
已完结
Human Pluripotent Stem Cell-Derived Blood Cells for Therapies
1个月前
已关闭
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach
2个月前
已完结
CAR T cells produced in vivo to treat cardiac injury
3个月前
已完结
FcγR1-Expressing Cell Membrane-Coated Nanoparticle (FcγR1-CMNP) for T-Cell-Engaging Bispecific Nanoantibody Construction
3个月前
已完结
Critical Considerations of mRNA-LNPs Technology for CAR-T Therapy: Components, Payloads and Emerging Horizons
3个月前
已完结
Differences and Similarities of the Intravenously Administered Lipid Nanoparticles in Three Clinical Trials: Potential Linkage between Lipid Nanoparticles and Extracellular Vesicles
3个月前
已完结
RNA-based nanomedicines and their clinical applications
3个月前
已完结
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
3个月前
已完结
皖公网安备34019202002308
